524506 Stock Overview
Coral Laboratories Limited manufactures and sells pharmaceutical formulations in India, Ethopia, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Coral Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹380.05 |
| 52 Week High | ₹498.10 |
| 52 Week Low | ₹225.00 |
| Beta | 1.07 |
| 1 Month Change | -4.12% |
| 3 Month Change | -13.13% |
| 1 Year Change | 47.39% |
| 3 Year Change | -5.53% |
| 5 Year Change | 17.90% |
| Change since IPO | 3,355.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 524506 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 3.3% | -0.5% | 1.4% |
| 1Y | 47.4% | 55.3% | 46.1% |
Return vs Industry: 524506 underperformed the Indian Pharmaceuticals industry which returned 55.3% over the past year.
Return vs Market: 524506 exceeded the Indian Market which returned 46.1% over the past year.
Price Volatility
| 524506 volatility | |
|---|---|
| 524506 Average Weekly Movement | 5.5% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: 524506 has not had significant price volatility in the past 3 months.
Volatility Over Time: 524506's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 109 | Girish Dhameja | corallab.com |
Coral Laboratories Limited manufactures and sells pharmaceutical formulations in India, Ethopia, and internationally. The company offers antibiotics/antibacterial products, including antifungal, antiemetic, analgesics/antipyretic/anti-inflammatory, antispasmodic, anticold, antiallergic, anti-asthmatic, anti-diabetic, anthelmentic, thyroid, and anti-protozoal/anti-amebic products; antimalarial drugs, antipsychotic drugs, gastro-intestinal drugs, kits, muscle relaxants, cough suppressant/expectorant products, cardiovascular medicines, oral antiseptic preparations, mouthwashes, calcium preparations, and appetizers; and nutritional, protein, and iron supplements, as well as other products. It also provides cephalosporin, beta lactam, and lyophilized injectable products; eye/ear/nose drops; nasal sprays and metered dose inhales; and large volume parenteral products.
Coral Laboratories Limited Fundamentals Summary
| 524506 fundamental statistics | |
|---|---|
| Market cap | ₹1.32b |
| Earnings (TTM) | ₹91.10m |
| Revenue (TTM) | ₹662.12m |
14.9x
P/E Ratio2.1x
P/S RatioIs 524506 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 524506 income statement (TTM) | |
|---|---|
| Revenue | ₹662.12m |
| Cost of Revenue | ₹330.86m |
| Gross Profit | ₹331.26m |
| Other Expenses | ₹240.16m |
| Earnings | ₹91.10m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 25.50 |
| Gross Margin | 50.03% |
| Net Profit Margin | 13.76% |
| Debt/Equity Ratio | 0.9% |
How did 524506 perform over the long term?
See historical performance and comparison